A new study shows that the way amyloid proteins—implicated in Alzheimer's disease—assemble into fibrils can be significantly ...

UCSF researchers have identified ADGRG1, a microglial receptor that helps clear amyloid beta plaques in Alzheimer’s disease.

Long-term extension data presented at the Alzheimer's Association International Conference showed amyloid plaque ...

Trontinemab is one of a class of new medicines aimed at clearing amyloid plaques. The new findings from phase two trials ...

In Alzheimer's disease, proteins like amyloid beta form clumps, known as plaques, that damage the brain. Subscribe to our ...

Scientists at UCSF have uncovered how certain immune cells in the brain, called microglia, can effectively digest toxic ...

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

TORONTO -- An investigational antibody drug, designed to cross the blood-brain barrier (BBB) to eliminate amyloid-beta ...

In a Phase Ib/IIa trial, 91% of patients receiving the highest dose of trontinemab were amyloid negative after seven months ...

Families across Georgia are finding new hope in the fight against Alzheimer’s disease, thanks to promising treatments at ...

Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...